Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7015233B2 · kind B2 · utility
19Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2003 |
| Grant date | Mar 21, 2006 |
| Priority date | — |
| Expiry date | Aug 22, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.